Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684

Journal of Clinical Oncology

Volumn 14, Issue 1, 1996, Pages 7-17

  Kirkwood, J M ^a   Strawderman, M H ^a   Ernstoff, M S ^a   Smith, T J ^a   Borden, E C ^a   Blum, R H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CHILL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAPHORESIS; DOSE RESPONSE; FATIGUE; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MELANOMA; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0030030347     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.1.7     Document Type: Article

References (13)

1. Balch CM, Soong S, Milton GW, et al: A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 196:677-684, 1982
2. Balch CM, Soong S, Murad TM, et al: A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 193:377-388, 1981
3. Balch CM, Murad TM, Soong SJ, et al: A multifactorial analysis of melanoma: Prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 188:732-742, 1978
4. Clark WH Jr, Elder DE, Guerry D IV, et al: Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893-1904, 1989
5. Kirkwood JM, Ernstoff MS: Interferons in the treatment of human cancer. J Clin Oncol 2:336-352, 1984
6. Kirkwood JM, Ernstoff MS: Interferons - Clinical applications: Cutaneous melanoma, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer. Philadelphia, PA, Lippincott, 1991, pp 311-333
7. Kirkwood JM, Agarwala S: Systemic cytotoxic and biologic therapy melanoma. PPO Updates 7:1-16, 1993
8. Kirkwood J, Hunt M, Smith T, et al: A randomized controlled trial of high-dose IFN alfa-2b for high-risk melanoma: The ECOG trial EST-1684. Proc Am Soc Clin Oncol 12:390, 1993 (abstr)
9. Wittes RE: Manual of Oncologic Therapeutics. Philadelphia, PA, Lippincott, 1989
10. Gray R: Some diagnostic methods for Cox regression models through hazard smoothing. Biometrics 46:93-102, 1990
11. Kirkwood JM, Ernstoff MS, Davis CA, et al: Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 103:32-36, 1985
12. Kirkwood JM: Biologic therapy with interferon α and β: Clinical applications - Melanoma, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer: Principles and Practice. Philadelphia, PA, Lippincott, 1995, pp 388-411
13. Cascinelli N: Evaluation of efficacy of adjuvant rIFNα 2A in melanoma patients with regional node metastases. Proc Am Soc Clin Oncol 14:410, 1995 (abstr)